整流方式에 따른 醫療用 X-線 裝置의 特性

김재문,권덕문,최세곤 嶺南大學校 工業技術硏究所 1995 工業技術硏究所論文集 Vol.23 No.2

The output characteristics on various rectification methods of X-ray equipments for the purpose of medical use are investigated by means of X-ray multimeter. in comparison the measured values with setting values, the accuracy of X-ray tube voltage and illumination time was varied in the range of +70% in case of three phase type including inverter type. The inverter type also showed a good reproducibility. As the experimental results, it is desirable that the inverter type X-ray equipment will be widely used in the near future.

ERRATUM : Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry

Kim, Ho Cheol,Jung, Chi Young,Cho, Deog Gon,Jeon, Jae Hyun,Lee, Jeong Eun,Ahn, Jin Seok,Kim, Seung Joon,Kim, Yeongdae,Kim, Young-Chul,Kim, Jung-Eun,Lee, Boram,Won, Young-Joo,Choi, Chang-Min The Korean Academy of Tuberculosis and Respiratory 2019 Tuberculosis and Respiratory Diseases Vol.82 No.3

Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

Kim, Chun-Hyung,Han, Baek-Soo,Moon, Jisook,Kim, Deog-Joong,Shin, Joon,Rajan, Sreekanth,Nguyen, Quoc Toan,Sohn, Mijin,Kim, Won-Gon,Han, Minjoon,Jeong, Inhye,Kim, Kyoung-Shim,Lee, Eun-Hye,Tu, Yupeng,Naf National Academy of Sciences 2015 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF Vol.112 No.28

<P><B>Significance</B></P><P>Parkinson’s disease (PD) is the most prevalent movement disorder with no available treatments that can stop or slow down the disease progress. Although the orphan nuclear receptor Nurr1 is a promising target for PD, it is thought to be a ligand-independent transcription factor and, so far, no small molecule has been identified that can bind to its ligand binding domain. Here, we established high throughput cell-based assays and successfully identified three Nurr1 agonists among FDA-approved drugs, all sharing an identical chemical scaffold. Remarkably, these compounds not only directly bind to Nurr1 but also ameliorate behavioral defects in a rodent model of PD. Thus, our study shows that Nurr1 could serve as a valid drug target for neuroprotective therapeutics of PD.</P><P>Parkinson’s disease (PD), primarily caused by selective degeneration of midbrain dopamine (mDA) neurons, is the most prevalent movement disorder, affecting 1–2% of the global population over the age of 65. Currently available pharmacological treatments are largely symptomatic and lose their efficacy over time with accompanying severe side effects such as dyskinesia. Thus, there is an unmet clinical need to develop mechanism-based and/or disease-modifying treatments. Based on the unique dual role of the nuclear orphan receptor Nurr1 for development and maintenance of mDA neurons and their protection from inflammation-induced death, we hypothesize that Nurr1 can be a molecular target for neuroprotective therapeutic development for PD. Here we show successful identification of Nurr1 agonists sharing an identical chemical scaffold, 4-amino-7-chloroquinoline, suggesting a critical structure–activity relationship. In particular, we found that two antimalarial drugs, amodiaquine and chloroquine stimulate the transcriptional function of Nurr1 through physical interaction with its ligand binding domain (LBD). Remarkably, these compounds were able to enhance the contrasting dual functions of Nurr1 by further increasing transcriptional activation of mDA-specific genes and further enhancing transrepression of neurotoxic proinflammatory gene expression in microglia. Importantly, these compounds significantly improved behavioral deficits in 6-hydroxydopamine lesioned rat model of PD without any detectable signs of dyskinesia-like behavior. These findings offer proof of principle that small molecules targeting the Nurr1 LBD can be used as a mechanism-based and neuroprotective strategy for PD.</P>

Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry

Kim, Ho Cheol,Jung, Chi Young,Cho, Deog Gon,Jeon, Jae Hyun,Lee, Jeong Eun,Ahn, Jin Seok,Kim, Seung Joon,Kim, Yeongdae,Kim, Young-Chul,Kim, Jung-Eun,Lee, Boram,Won, Young-Joo,Choi, Chang-Min The Korean Academy of Tuberculosis and Respiratory 2019 Tuberculosis and Respiratory Diseases Vol.82 No.2

Background: Lung cancer is a leading cause of morbidity and mortality worldwide, and the incidence continues to rise. Although many prognostic factors have been identified, the clinical characteristics and outcomes in Korean lung cancer patients are not well defined. Methods: Of the 23,254 new lung cancer cases registered at the Korea Central Cancer Registry in 2013, total 489 patients from 19 hospitals were abstracted by the Korean Central Cancer Registry. The clinical data retrospectively analyzed, patients were followed up until December 2015. Results: The median age was 69 years (interquartile range, 60-74 years); 65.4% were male and 62.1% were ever-smokers. Cough was the most common initial symptom (33.5%); 13.1% of patients were asymptomatic. While squamous cell carcinoma was the most common subtype in male patients (37.2%), adenocarcinoma was the most frequent histological type in all patients (48.7%) and females (76.3%). The majority of patients received treatment (76.5%), which included surgery, radiation therapy, and chemotherapy. Older age (hazard ratio [HR], 1.037), lower body mass index (HR, 0.904), ever-smoker (HR, 2.003), small cell lung cancer (HR, 1.627), and distant metastasis (HR, 3.990) were independent predictors of mortality. Patients without symptoms (HR, 0.387) and without treatment (HR, 0.364) were associated with a favorable outcome in multivariate Cox analysis. Conclusion: Lung cancer in Korea occurs predominantly in elderly patients, with adenocarcinoma being the most frequent subtype. The prognosis was poorer in ever-smokers and older, malnourished, and untreated patients with advanced lung cancer.

한국한의학과 인도전통의학의 비교연구

김덕곤(Deog-Gon Kim) 대한한의학회 2005 대한한의학회지 Vol.26 No.2

Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry

( Ho Cheol Kim ),( Chi Young Jung ),( Deog Gon Cho ),( Jae Hyun Jeon ),( Jeong Eun Lee ),( Jin Seok Ahn ),( Seung Joon Kim ),( Yeongdae Kim ),( Young-chul Kim ),( Jung-eun Kim ),( Boram Lee ),( Young- 대한결핵 및 호흡기학회 2019 Tuberculosis and Respiratory Diseases Vol.82 No.3

Paclitaxel 매주 투여 및 방사선치료 동시요법을 받은 국소진행성 비소세포폐암 환자들의 치료 결과

김수지(Suzy Kim),김성환(Sung Whan Kim),심병용(Byoung Yong Shim),김치홍(Chi Hong Kim),송소향(So Hyang Song),안명임(Meyung Im Ahn),조덕곤(Deog Gon Cho),조규도(Kyu Do Cho),유진영(Jinyoung Yoo),김훈교(Hoon Kyo Kim) 대한방사선종양학회 2006 Radiation Oncology Journal Vol.24 No.4

목 적: 국소진행성 비소세포폐암 환자에 대한 매주 paclitaxel 항암화학요법과 방사선치료 동시 요법의 안정성과 효 과를 알아보고 재발 양상 및 생존율을 분석하고자 하였다. 대상 및 방법: 1999년 10월부터 2004년 9월까지 국소진행성 비소세포폐암으로 진단받고 근치적 목적으로 항암화 학방사선 동시요법을 시행 받은 환자 23명을 대상으로 후향적 분석을 시행하였다. 방사선치료는 일일 1회 1.8 Gy 씩 주5회 분할 조사하여 7∼8주에 걸쳐 총 선량 55.8∼64.8 (median 64.8) Gy를 조사하였다. 항암화학요법은 매주 paclitaxel 50 또는 60 mg/m2 용량으로 방사선치료 1일, 8일, 15일, 22일, 29일 36일째에 투여하였다. 항암화학방사선동시요법을 마친 4주 후부터 paclitaxel 135 mg/m2와 cisplatin 75 mg/m2 용량으로 3주 간격으로 3주기의 공고 항암화학요법을 추가 시행하였다. 결 과: 동시 항암화학방사선요법을 시행받은 23명의 환자 중 3명이 도중에 환자 임의로 치료를 중단하였고 1명이 5,580 cGy까지 방사선치료를 시행 받고 세균성 폐렴으로 사망하였다. 주된 급성 부작용은 방사선 식도염으로 4명(17%)의 환자에서 2도의 식도염이 관찰되었으며 3도 이상의 부작용은 관찰되지 않았다. 16명의 환자가 추가 공고항암화학요법을 시행 받았으며 공고 항암화학요법 중의 급성 부작용으로 3도 이상의 호중구 감소증이 8명(50%)의 환자에서 관찰되었으며 그중 한 명은 패혈증으로 사망하였다. 동시 항암화학방사선요법을 끝까지 시행 받은 20명의 환자에서 치료에 대한 반응을 조사할 수 있었으며 완전 관해 4명(20%), 부분 관해 14명(70%)으로 전체 관해율은 90%이었다. 관해를 보인 환자들 중 추적 관찰이 가능했던 16명 중 14명에서 재발이 확인되었고 국소 재발이 9명(56%), 국소 재발과 원격 전이가 3명(19%), 원격 전이가 2명(13%)이었다. 동시 항암화학방사선요법을 끝까지 시행받은 환자들에서의 무진행 생존 기간의 중앙값은 9.5개월이었으며, 2년 무진행 생존율은 18%이었다. 재발된 환자중 11명에서 2차(second-line) 또는 3차(third-line) 항암화학요법이 시행되었다. 전체 환자 23명의 중앙 생존 기간은 21개월, 2년 및 5년 생존율은 각각 43%, 33%였다. 다변량 분석을 시행했을 때 환자의 나이, 수행 능력, 종양의 크기는 무진행 생존율에 영향을 주는 유의한 예후 인자로 나타났다. 결 론: 국소진행성 비소세포폐암 환자에서 paclitaxel 매주 투여 항암화학요법과 방사선치료 동시요법은 안전하고 종양의 관해율도 높았다. 그러나 국소 재발률이 높고 특히 종양의 크기가 큰 환자에서 예후가 나쁜 것을 알 수 있었다. 따라서 향후 부작용은 증가시키지 않으면서 국소제어율을 향상시키기 위한 노력이 필요하다. Purpose: To analyze the response, toxicity, patterns of failure and survival rate of patients with locally advanced non-small cell lung cancer who were treated with concurrent chemoradiotherapy with weekly paclitaxel. Materials and Methods: Twenty-three patients with locally advanced non-small cell lung cancer patients who received radical chemoradiotherapy from October 1999 to September 2004 were included in this retrospective study. Patients received total 55.4∼64.8 (median 64.8) Gy (daily 1.8 Gy per fraction, 5 days per weeks) over 7∼8 weeks. 50 or 60 mg/m2 of paclitaxel was administered on day 1, 8, 15, 22, 29 and 36 of radiotherapy. Four weeks after the concurrent chemoradiotherapy, three cycles of consolidation chemotherapy consisted of aclitaxel 135 mg/m2 and cisplatin 75 mg/m2 was administered every 3 weeks. Results: Of the 23 patients, 3 patients refused to receive the treatment during the concurrent chemoradiotherapy. One patient died of bacterial eumonia during the concurrent chemoradiotherapy. Grade 2 radiation esophagitis was observed in 4 patients (17%). Sixteen patients received consolidation chemotherapy. During the consolidation chemotherapy, 8 patients (50%) experienced grade 3 or 4 neutropenia and one of those patients died of neutropenic sepsis. Overall response rate for 20 evaluable patients was 90% including 4 complete responses (20%) and 14 partial responses (70%). Among 18 responders, 9 had local failure, 3 had local and distant failure and 2 had distant failure only. Median progression-free survival time was 9.5 months and 2-year progression-free survival rate was 19%. Eleven patients received second-line or third-line chemotherapy after the treatment failure. The median overall survival time was 21 months. 2-year and 5-year survival rate were 43% and 33%, respectively. Age, performance status, tumor size were significant prognostic factors for progression-free survival. Conclusion: Concurrent chemoradiotherapy with weekly paclitaxel revealed high response rate and low toxicity rate. But local failure occurred frequently after the remission and large tumor size was a poor prognostic factor. Further investigations are needed to improve the local control.

Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry

( Ho Cheol Kim ),( Chi Young Jung ),( Deog Gon Cho ),( Jae Hyun Jeon ),( Jeong Eun Lee ),( Jin Seok Ahn ),( Seung Joon Kim ),( Yeongdae Kim ),( Young-chul Kim ),( Jung-eun Kim ),( Boram Lee ),( Young- 대한결핵 및 호흡기학회 2019 Tuberculosis and Respiratory Diseases Vol.82 No.2

Background: Lung cancer is a leading cause of morbidity and mortality worldwide, and the incidence continues to rise. Although many prognostic factors have been identified, the clinical characteristics and outcomes in Korean lung cancer patients are not well defined. Methods: Of the 23,254 new lung cancer cases registered at the Korea Central Cancer Registry in 2013, total 489 patients from 19 hospitals were abstracted by the Korean Central Cancer Registry. The clinical data retrospectively analyzed, patients were followed up until December 2015. Results: The median age was 69 years (interquartile range, 60-74 years); 65.4% were male and 62.1% were ever-smokers. Cough was the most common initial symptom (33.5%); 13.1% of patients were asymptomatic. While squamous cell carcinoma was the most common subtype in male patients (37.2%), adenocarcinoma was the most frequent histological type in all patients (48.7%) and females (76.3%). The majority of patients received treatment (76.5%), which included surgery, radiation therapy, and chemotherapy. Older age (hazard ratio [HR], 1.037), lower body mass index (HR, 0.904), ever-smoker (HR, 2.003), small cell lung cancer (HR, 1.627), and distant metastasis (HR, 3.990) were independent predictors of mortality. Patients without symptoms (HR, 0.387) and without treatment (HR, 0.364) were associated with a favorable outcome in multivariate Cox analysis. Conclusion: Lung cancer in Korea occurs predominantly in elderly patients, with adenocarcinoma being the most frequent subtype. The prognosis was poorer in ever-smokers and older, malnourished, and untreated patients with advanced lung cancer.

Effect of <i>Achyranthes bidentata</i> Blume on 3T3-L1 Adipogenesis and Rats Fed with a High-Fat Diet

Oh, Sang Deog,Kim, Mihyun,Min, Byung-Il,Choi, Gi Soon,Kim, Sun-Kwang,Bae, Hyunsu,Kang, Chulhun,Kim, Deok-Gon,Park, Byoung-Jin,Kim, Chang Keun Hindawi Publishing Corporation 2014 Evidence-based Complementary and Alternative Medic Vol.2014 No.-

<P>The present study investigated the antiobesity effect of <I>Achyranthes bidentata</I> Blume root water extract in a 3T3-L1 adipocyte differentiation model and rats fed with a high-fat diet. To investigate the effect of <I>Achyranthes bidentata</I> Blume on adipogenesis <I>in vitro</I>, differentiating 3T3-L1 cells in adipocyte-induction media were treated every two days with <I>Achyranthes bidentata</I> Blume at various concentrations (1 to 25 <I><I>μ</I></I>g/mL) for eight days. We found that <I>Achyranthes bidentata</I> Blume root inhibited 3T3-L1 adipocyte differentiation without affecting cell viability, and Western blot analysis revealed that phospho-Akt expression was markedly decreased, whereas there was no significant change in perilipin expression. Furthermore, administration of <I>Achyranthes bidentata</I> Blume root (0.5 g/kg body weight for six weeks) to rats fed with a high-fat diet significantly reduced body weight gain without affecting food intake, and the level of triglyceride was significantly decreased when compared to those in rats fed with only a high-fat diet. These results suggest that <I>Achyranthes bidentata</I> Blume root water extract could have a beneficial effect on inhibition of adipogenesis and controlling body weight in rats fed with a high-fat diet.</P>

매실 분획물에 의한 인체 대장암세포 억제 효과

김정호(Jeong-Ho Kim),조현동(Hyun-Dong Cho),원영선(Yeong-Seon Won),허지안(Ji-An Heo),김지영(Ji-Young Kim),김휘곤(Hwi-Gon Kim),한심희(Sim-Hee Han),문광덕(Kwang-Deog Moon),서권일(Kwon-Il Seo) 한국생명과학회 2019 생명과학회지 Vol.29 No.11

매실은 한국, 일본 및 중국 등지에서 섭취하여온 과실로서 유기산이 풍부하며, 다량의 무기질 및 폴리페놀 성분을 함유한 것으로 알려져 있다. 이러한 매실을 이용하여 예로부터 절임이나 청 등으로 가공하여 섭취할 뿐만 아니라 구토, 해독 및 해열에 효능이 있는 한약재로서 사용해왔다. 본 연구에서는 매실을 이용하여 분획물을 제조하고 각각의 인체 대장암세포에 대한 성장 억제효과를 확인하였으며, colony 형성능, 형태학적 관찰, apoptotic body 형성, 단백질 변화 및 환경호르몬에 대한 방어 효과를 평가하였다. 매실 분획물의 인체 대장암세포 HT-29에 대한 증식 억제효과는 매실 메탄올 분획물(maesil methanol fraction, MMF) 및 매실 부탄올 분획물(maesil, butanol fraction, MBF)이 가장 뛰어난 효능을 나타내었다. MMF 및 MBF의 처리에 따라 colony 형성능 또한 농도의존적으로 감소하는 것으로 나타났으며 형태학적 변화 또한 확인할 수 있었다. 핵의 형태학적 변화를 관찰한 결과 125 μg/ml의 MMF 및 MBF 처리에 따라 apoptotic body의 형성 및 핵 응축을 관찰하였다. MMF 및 MBF의 처리에 따른 인체 대장암세포의 성장 억제효과가 apoptosis 와 관련이 있는지 단백질의 변화를 확인한 결과, pro-apoptotic 단백질은 Bax, caspase-3, PARP의 발현이 농도의존적으로 증가하는 경향을 나타내었으며, anti-apoptotic 단백질인 Bcl-2의 발현은 감소하는 경향을 나타냈다. 또한, 환경호르몬의 일종은 bisphenol A (BPA)에 의해 성장이 증식된 HT-29세포는 MMF의 처리에 따라 유의적인 성장억제 효과를 갖는 것을 확인할 수 있었다. 따라서 본 연구를 통해 얻은 결과는 매실 분획물을 이용한 기능성 식품 소재화에 대한 기초 자료로 활용될 수 있을 것으로 판단된다. Prunus mume, also known as maesil, is a popular fruit consumed in East Asia (Korea, Japan, and China). It contains high amounts of organic acids, minerals, and polyphenols and has been used as a medication for fever, vomiting, and detoxification. In this study, the anti-proliferative and apoptotic effects of solvent fractions from maesil were evaluated using sulforhodamine B (SRB) assays, morphological evaluations, Hoechst 33258 staining, and western blotting. Addition of the maesil methanol fraction (MMF) and the maesil butanol fraction (MBF) significantly and dose-dependently decreased the cell viability of HT-29 human colon cancer cells. Colony-forming assays confirmed that the MMF and MBF treatments decreased colony numbers when compared with untreated control cells. Treatment of HT-29 cells with MMF and MBF caused a distortion of the cell morphology to a shrunken cell mass. Treatment with MMF and MBF also dose-dependently increased nuclear condensation and the formation of apoptotic bodies in HT-29 cells. Treatment with MMF and MBF significantly and dosedependently increased the expression of Bax (a pro-apoptotic protein), caspase-3, and poly ADP-ribose polymerase (PARP) and decreased the expression of Bcl-2 (an anti-apoptotic protein). MMF significantly and dose-dependently inhibited cell proliferation induced by bisphenol A, an environmental hormone. Therefore, MMF may have potential use as a functional food and as a possible therapeutic agent for the prevention of colon cancer.